On May 30, 2019 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, reported that Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea, will participate in the following investor and industry conferences in June (Press release, Aeglea BioTherapeutics, MAY 30, 2019, View Source [SID1234536703]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2019 Healthcare Conference

Date:Wednesday, June 5, 2019

Presentation Time:8:30 a.m. ET

Location:New York, NY

Webcast:View Source

BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

Date:Tuesday, June 25, 2019

Presentation Time:11:40 a.m. ET

Location:New York, NY

Webcast:View Source

BIO International Convention

Date:Tuesday, June 4, 2019

Presentation Time:3:15 p.m. ET

Location:Philadelphia, PA

On May 30, 2019 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd., wet age‐related macular degeneration, reported that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the Jefferies 2019 Healthcare Conference at 2:30 pm EDT on Friday, June 7, 2019, in New York, NY (Press release, Tracon Pharmaceuticals, MAY 30, 2019, View Source [SID1234536702]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentations" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

On May 30, 2019 Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory, cancer and other diseases, reported that Stephen Yoder, President and Chief Executive Officer of Pieris Pharmaceuticals, Inc., will present at the Jefferies 2019 Healthcare Conference in New York, New York on Thursday, June 6, 2019 at 3:30 PM (EDT) (Press release, Pieris Pharmaceuticals, MAY 30, 2019, View Source [SID1234536701]). A webcast of the company’s presentation will be available at this link.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 30, 2019 Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, reported that Bahija Jallal, Chief Executive Officer, and David Berman, Head of Research and Development, will be presenting at the Jefferies 2019 Global Healthcare Conference in New York on Friday 7 June at 2:30pm ET (Press release, Immunocore, MAY 30, 2019, View Source [SID1234536700]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For meeting requests, please contact Julian Hirst at [email protected].

On May 30, 2019 argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported that management will present at two upcoming investor conferences in June (Press release, argenx, MAY 30, 2019, View Source [SID1234536699]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2019 Global Healthcare Conference. Company presentation on Thursday, June 6, 2019 at 10:30 a.m. ET in New York.

Goldman Sachs 40th Annual Global Healthcare Conference. Fireside chat on Wednesday, June 12, 2019 at 11:20 a.m. PT in Palos Verdes.

Live webcasts of each presentation will be available on the Company’s website at www.argenx.com. Replays of the webcasts will be available for 90 days following each presentation.